BG three-lens brief
Evidence-based stock research on BG. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Negative free cash flow last quarterly (-$3.02B).
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Analyst mean target $139.22 — 39% above current (9 analysts).
- Negative free cash flow last quarterly (-$3.02B).
- Reported earnings on 2026-10-29.
- Ex-dividend date 2026-11-17.
BG closed at $100.28 (+0.86%) as of 2026-11-12. Market cap: $19.27B. P/E (trailing) 17.2. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $139.22 — 39% above current (9 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; negative free cash flow last quarterly (-$3.02B).. Last quarter: Revenue $23.80B, net income $318.00M, free cash flow -$3.02B.
Why three lenses on BG, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BG across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BG" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BG brief"></iframe>